What Deverra Therapeutics does

Deverra Therapeutics, Inc. is a privately held, clinical-stage biotechnology company headquartered in Seattle, Washington, founded in 2019 to develop allogeneic, off-the-shelf universal donor cellular immunotherapies for cancer and infectious disease. The company's core technology is an exclusively licensed Notch-mediated stem cell expansion and directed differentiation platform, originally developed over more than 20 years of federally funded research at the Fred Hutchinson Cancer Research Center. The platform uses pooled umbilical cord blood-derived hematopoietic stem and progenitor cells (HSPCs) to generate multiple distinct cell types — including stem and progenitor cells, natural killer (NK) cells, and myeloid cells — that require no donor-patient HLA matching and can be cryopreserved for immediate, on-demand clinical use.

The company's lead clinical asset, dilanubicel, is a stem and progenitor cell therapy being evaluated in a global Phase 2 randomized controlled trial as an adjuvant to standard-of-care chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients; data from the study demonstrated a statistically significant increase in remission rates, and 27 of 28 participants survived at least one year without severe rejection symptoms. A second clinical asset, DVX201 (unmodified NK cells), has completed two Phase 1 trials in COVID-19 and relapsed/refractory AML/high-risk MDS and has been out-licensed to Coeptis Therapeutics for further development and commercialization. Preclinical programs include engineered CAR-NK cells and engineered monocyte/macrophage therapies targeting solid tumors. Dilanubicel received FDA Orphan Drug Designation in February 2024 and RMAT Designation in March 2024.

Deverra is pre-revenue, with a headcount of 11–50 employees, and generates income through one-time licensing transactions (e.g., the DVX201 out-license to Coeptis) and royalties, with future revenue expected from product sales upon regulatory approval. Distribution of investigational products occurs through regulated clinical trial sites in partnership with Fred Hutchinson Cancer Center, the University of Washington, Duke University, and Novant Health. The company is also positioned to license out additional NK and myeloid cell programs, and is actively hiring across research, manufacturing, and clinical functions.

Name

Deverra Therapeutics

Legal name

Deverra Therapeutics, Inc.

Website

https://deverratx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Deverra Therapeutics is a Seattle-based, clinical-stage biotechnology company developing allogeneic, off-the-shelf universal donor cellular immunotherapies for cancer and infectious disease using an exclusively licensed Notch-mediated stem cell expansion platform from Fred Hutchinson Cancer Research Center, with its lead asset dilanubicel in a global Phase 2 trial for acute myeloid leukemia.

Ownership category

akta.pro rank

Product category

Cellular Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

NK Cell Therapies (HLAAABAD), Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO)

Keywords

• Allogeneic cell therapy
• Cellular immunotherapy
• NK cell therapy
• Stem cell therapy
• Biopharmaceutical development

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Biopharmaceutical product revenue: Pre-revenue clinical-stage company developing allogeneic cell therapy products for cancer and infectious diseases. Revenue will be generated through product sales upon regulatory approval.
2. Licensing and partnership revenue: DVX201 NK cell products have been out-licensed to Coeptis Therapeutics, generating licensing revenue. The company also holds exclusive license to its platform technology.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Deverra Therapeutics develops allogeneic, off-the-shelf universal donor cellular immunotherapies manufactured from pooled umbilical cord blood using its proprietary Notch-mediated stem cell expansion and directed differentiation platform. Its clinical pipeline includes the lead product dilanubicel (stem and progenitor cells for acute myeloid leukemia), DVX201 (NK cells out-licensed to Coeptis Therapeutics), and preclinical CAR-NK and engineered monocyte/macrophage therapies for hematologic malignancies and solid tumors.

Product overview

Deverra Therapeutics is a clinical stage biotechnology company developing allogeneic, off-the-shelf universal donor cellular immunotherapies built on a proprietary Notch-mediated stem cell expansion and directed differentiation platform licensed from the Fred Hutchinson Cancer Research Center. The platform generates multiple cell types including stem and progenitor cells (lead product: Dilanubicel), natural killer (NK) cells (DVX201, now licensed to Coeptis Therapeutics), and myeloid cells. The company also develops engineered variants including CAR-NK cells and engineered monocyte/macrophage therapies for hematologic malignancies and solid tumors. All products are universal donor (no HLA matching required) and cryopreserved for immediate on-demand use.

Differentiator

Problem solved

Functional benefit

Brands

• Dilanubicel: Stem and progenitor cell therapy derived from cord blood, intended for use as a non-engrafting adjuvant cell therapy with chemotherapy to enhance remission rates and improve overall survival in AML patients.
• DVX201

Products and services

• Dilanubicel Stem and progenitor cell therapy derived from pooled umbilical cord blood, designed as a non-engrafting adjuvant cell therapy to enhance remission rates and improve overall survival in Acute Myeloid Leukemia (AML) patients when combined with standard-of-care chemotherapy. Lead product; evaluated in a global Phase 2 randomized controlled trial in newly diagnosed AML.
• DVX201 Unmodified natural killer (NK) cell product generated from cord blood HSPCs using the Notch-mediated differentiation platform, intended to fight cancer and viral infections. Safely dosed in two Phase 1 clinical trials and now out-licensed to Coeptis Therapeutics.
• CAR-NK Cells Engineered chimeric antigen receptor natural killer (CAR-NK) cell therapy designed to target specific cancers with enhanced potency. Preclinical/IND-enabling pipeline asset.
• Unmodified Myeloid Cells (Monocytes/Macrophages) Unmodified monocytes and macrophages generated from cord blood HSPCs, designed to phagocytose abnormal cells, bacteria, and pathogens, and to activate and educate other immune cells by releasing cytokines and presenting antigens.
• Engineered Monocyte/Macrophage Cell Therapies Engineered monocyte and macrophage cell therapies designed for solid tumor treatment, intended to be used alone or in combination with other cell therapy products; may be engineered to secrete stimulatory cytokines to recruit additional immune cells and enhance killing of resistant solid tumor cells.

Quantifiable outcome

• 27 of 28 participants (96.4%) survived at least one year without severe rejection symptoms in phase 2 clinical trial
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Fred Hutchinson Cancer Research CentercoreStrategic or Co-development PartnerDeverra has an exclusive license to the proprietary Notch-mediated stem cell expansion and directed differentiation platform from Fred Hutchinson Cancer Research Center. The center has over 20 years of federally funded research in this technology. Researchers from Fred Hutch collaborated on the dilanubicel clinical trial published in Journal of Clinical Oncology.
• Coeptis TherapeuticscoreChannel Partner/ Reseller/ DistributorDVX201 NK cell product has been safely dosed in two Phase 1 clinical trials (DVX201-COV-01 for COVID-19 and DVX201-AML-01 for AML/MDS), now licensed to Coeptis Therapeutics for further development and commercialization. Deverra aims to license out additional NK and myeloid cell programs.
• University of WashingtoncoreStrategic or Co-development PartnerClinical trial partner for DVX201-COV-01 Phase 1 study testing allogeneic NK cell therapy in subjects hospitalized for COVID-19.
• Novant HealthminorStrategic or Co-development PartnerClinical trial partner for DVX201-AML-01 study evaluating safety and efficacy of DVX201 NK cells in patients with relapsed/refractory AML or high-risk MDS.
• Duke UniversityminorStrategic or Co-development PartnerClinical trial partner for dilanubicel study in acute myeloid leukemia.
• National Cord Blood Program (NCBP)coreOthersCord blood bank partner providing sustainable, healthy donor umbilical cord blood cells as starting material for Deverra's cell therapy platform.
• CariCord (CCB)coreOthersCord blood bank partner providing sustainable, healthy donor umbilical cord blood cells as starting material for Deverra's cell therapy platform.
• New York Blood Bank (NYBB)minorOthersResearch partner providing cord blood resources for research and development activities.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• VOR BioPharma: Focused on allogeneic cell therapies for patients with hematologic malignancies, particularly AML. Comparable disease focus and allogeneic approach to engineered hematopoietic cells.
• Nkarta Therapeutics: Focused on allogeneic, off-the-shelf NK cell therapies engineered with CARs for cancer, including AML. Closely aligned with Deverra's DVX201 and CAR-NK programs and shares the universal donor positioning.
• Gamida Cell: Commercializes an FDA-approved cell therapy (Omisirge) for patients with hematologic malignancies undergoing umbilical cord blood transplantation. Direct overlap in cord blood-derived cell therapies for AML/transplant.
• Celularity: Uses placenta and cord blood-derived cells to develop off-the-shelf allogeneic cell therapies, including NK cell candidates for AML and other cancers. Highly comparable raw material and universal donor positioning to Deverra.
• Fate Therapeutics: Clinical-stage biotech developing off-the-shelf, allogeneic NK and T cell therapies from a renewable iPSC platform. Directly comparable to Deverra in modality (universal donor cell therapy) and target indications including hematologic malignancies.
• Caribou Biosciences: Clinical-stage company developing allogeneic CAR-T and CAR-NK cell therapies using CRISPR-based gene editing. Overlaps with Deverra in engineered, universal donor immune effector cell therapies for cancer.
• Shoreline Biosciences: Develops allogeneic, off-the-shelf NK cell therapies derived from induced pluripotent stem cells. Comparable modality (universal donor NK) and emerging pipeline in hematologic malignancies.
• Century Therapeutics: Developing allogeneic, iPSC-derived immune cell therapies (NK and T cells) for hematologic and solid tumors. Comparable in platform philosophy (renewable, universal donor cell source) and oncology focus.

Broad incumbents

• Allogene Therapeutics: Pioneering allogeneic CAR-T therapies across multiple hematologic malignancies. A larger, broader incumbent in the allogeneic cell therapy space with overlapping clinical ambitions in B-cell malignancies and beyond.
• Kiadis Pharma (a Sanofi company): Acquired by Sanofi, developed allogeneic NK cell platforms (PM21 particles) for cancer and infectious diseases. Provides a benchmark for an NK platform that scaled via strategic acquisition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deverra Therapeutics